Cargando…

Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy

Allergen-specific immunotherapy is the only curative treatment of honeybee venom (HBV) allergy, which is able to protect against further anaphylactic sting reactions. Recent analyses on a molecular level have demonstrated that HBV represents a complex allergen source that contains more relevant majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Blank, Simon, Etzold, Stefanie, Darsow, Ulf, Schiener, Maximilian, Eberlein, Bernadette, Russkamp, Dennis, Wolf, Sara, Graessel, Anke, Biedermann, Tilo, Ollert, Markus, Schmidt-Weber, Carsten B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647995/
https://www.ncbi.nlm.nih.gov/pubmed/28494206
http://dx.doi.org/10.1080/21645515.2017.1323603
_version_ 1783272323949789184
author Blank, Simon
Etzold, Stefanie
Darsow, Ulf
Schiener, Maximilian
Eberlein, Bernadette
Russkamp, Dennis
Wolf, Sara
Graessel, Anke
Biedermann, Tilo
Ollert, Markus
Schmidt-Weber, Carsten B.
author_facet Blank, Simon
Etzold, Stefanie
Darsow, Ulf
Schiener, Maximilian
Eberlein, Bernadette
Russkamp, Dennis
Wolf, Sara
Graessel, Anke
Biedermann, Tilo
Ollert, Markus
Schmidt-Weber, Carsten B.
author_sort Blank, Simon
collection PubMed
description Allergen-specific immunotherapy is the only curative treatment of honeybee venom (HBV) allergy, which is able to protect against further anaphylactic sting reactions. Recent analyses on a molecular level have demonstrated that HBV represents a complex allergen source that contains more relevant major allergens than formerly anticipated. Moreover, allergic patients show very diverse sensitization profiles with the different allergens. HBV-specific immunotherapy is conducted with HBV extracts which are derived from pure venom. The allergen content of these therapeutic extracts might differ due to natural variations of the source material or different down-stream processing strategies of the manufacturers. Since variations of the allergen content of therapeutic HBV extracts might be associated with therapeutic failure, we adressed the component-resolved allergen composition of different therapeutic grade HBV extracts which are approved for immunotherapy in numerous countries. The extracts were analyzed for their content of the major allergens Api m 1, Api m 2, Api m 3, Api m 5 and Api m 10. Using allergen-specific antibodies we were able to demonstrate the underrepresentation of relevant major allergens such as Api m 3, Api m 5 and Api m 10 in particular therapeutic extracts. Taken together, standardization of therapeutic extracts by determination of the total allergenic potency might imply the intrinsic pitfall of losing information about particular major allergens. Moreover, the variable allergen composition of different therapeutic HBV extracts might have an impact on therapy outcome and the clinical management of HBV-allergic patients with specific IgE to particular allergens.
format Online
Article
Text
id pubmed-5647995
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-56479952017-11-01 Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy Blank, Simon Etzold, Stefanie Darsow, Ulf Schiener, Maximilian Eberlein, Bernadette Russkamp, Dennis Wolf, Sara Graessel, Anke Biedermann, Tilo Ollert, Markus Schmidt-Weber, Carsten B. Hum Vaccin Immunother Research Paper Allergen-specific immunotherapy is the only curative treatment of honeybee venom (HBV) allergy, which is able to protect against further anaphylactic sting reactions. Recent analyses on a molecular level have demonstrated that HBV represents a complex allergen source that contains more relevant major allergens than formerly anticipated. Moreover, allergic patients show very diverse sensitization profiles with the different allergens. HBV-specific immunotherapy is conducted with HBV extracts which are derived from pure venom. The allergen content of these therapeutic extracts might differ due to natural variations of the source material or different down-stream processing strategies of the manufacturers. Since variations of the allergen content of therapeutic HBV extracts might be associated with therapeutic failure, we adressed the component-resolved allergen composition of different therapeutic grade HBV extracts which are approved for immunotherapy in numerous countries. The extracts were analyzed for their content of the major allergens Api m 1, Api m 2, Api m 3, Api m 5 and Api m 10. Using allergen-specific antibodies we were able to demonstrate the underrepresentation of relevant major allergens such as Api m 3, Api m 5 and Api m 10 in particular therapeutic extracts. Taken together, standardization of therapeutic extracts by determination of the total allergenic potency might imply the intrinsic pitfall of losing information about particular major allergens. Moreover, the variable allergen composition of different therapeutic HBV extracts might have an impact on therapy outcome and the clinical management of HBV-allergic patients with specific IgE to particular allergens. Taylor & Francis 2017-05-11 /pmc/articles/PMC5647995/ /pubmed/28494206 http://dx.doi.org/10.1080/21645515.2017.1323603 Text en © 2017 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Research Paper
Blank, Simon
Etzold, Stefanie
Darsow, Ulf
Schiener, Maximilian
Eberlein, Bernadette
Russkamp, Dennis
Wolf, Sara
Graessel, Anke
Biedermann, Tilo
Ollert, Markus
Schmidt-Weber, Carsten B.
Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy
title Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy
title_full Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy
title_fullStr Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy
title_full_unstemmed Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy
title_short Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy
title_sort component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647995/
https://www.ncbi.nlm.nih.gov/pubmed/28494206
http://dx.doi.org/10.1080/21645515.2017.1323603
work_keys_str_mv AT blanksimon componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT etzoldstefanie componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT darsowulf componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT schienermaximilian componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT eberleinbernadette componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT russkampdennis componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT wolfsara componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT graesselanke componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT biedermanntilo componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT ollertmarkus componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy
AT schmidtwebercarstenb componentresolvedevaluationofthecontentofmajorallergensintherapeuticextractsforspecificimmunotherapyofhoneybeevenomallergy